Fluticasone Propionate _ c25h31f3o5s - Pubchem

8/18/2019 Fluticasone Propionate _ c25h31f3o5s - Pubchem

1/51

NIH U.S. National Library of Medicine National Center for Biotechnology Information

D A T A B A S E

Search Compounds

PUBCHEM COMPOUND FLUTICASONE PROPIONATE

FLUTICASONE PROPIONATE Cite this Record

Vendors

DrugInformation

Pharmacology

Literature

Patents

Bioactivities

PubChem CID: 444036

Chemical Names:FLUTICASONE PROPIONATE; Cutivate; Flonase; Flovent;

Flixonase; Flixotide; More...

Molecular Formula: C H F O S

Molecular Weight: 500.57085 g/mol

InChI Key: WMWTYOKRWGGJOA-CENSZEJFSA-N

UNII: O2GMZ0LF5W

Modify Date: 2015-10-31Create Date: 2005-06-24

Fluticasone Propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoidreceptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of theglucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2,which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins andleukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads todephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription.Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.

Pharmacology from NCIt

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory andpruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergicrhinitis, and orally for the treatment of asthma. Fluticasone proprionate is marketed under several different brandnames such as Flonase®. Fluticasone propionate is also available as a combination product of azelastinehydrochloride and fluticasone propionate called Dymista(TM). Dymista(TM) is indicated in patients over 12 yearsold for symptomatic relief of seasonal allergic rhinitis.

from DrugBank

25 31 3 5

http://pubchem.ncbi.nlm.nih.gov/compound/azelastine%20hydrochloridehttp://pubchem.ncbi.nlm.nih.gov/compound/Dymistahttp://pubchem.ncbi.nlm.nih.gov/compound/azelastine%20hydrochloridehttp://pubchem.ncbi.nlm.nih.gov/http://www.ncbi.nlm.nih.gov/pccompoundhttp://pubchem.ncbi.nlm.nih.gov/http://pubchem.ncbi.nlm.nih.gov/http://www.nih.gov/http://www.nlm.nih.gov/http://www.ncbi.nlm.nih.gov/http://pubchem.ncbi.nlm.nih.gov/compound/Dymistahttp://pubchem.ncbi.nlm.nih.gov/compound/Dymistahttp://pubchem.ncbi.nlm.nih.gov/compound/azelastine%20hydrochloridehttp://pubchem.ncbi.nlm.nih.gov/compound/Fluticasonehttp://pubchem.ncbi.nlm.nih.gov/compound/fluticasonehttp://pubchem.ncbi.nlm.nih.gov/compound/propionatehttp://www.accessdata.fda.gov/spl/data/882786d7-2873-4997-8d3c-b5a403bc0fec/882786d7-2873-4997-8d3c-b5a403bc0fec.xmlhttp://pubchem.ncbi.nlm.nih.gov/search/#collection=compounds&query_type=mf&query=C25H31F3O5S&sort=mw&sort_dir=aschttp://www.ncbi.nlm.nih.gov/pccompoundhttp://pubchem.ncbi.nlm.nih.gov/http://pubchem.ncbi.nlm.nih.gov/http://www.ncbi.nlm.nih.gov/http://www.nlm.nih.gov/http://www.nih.gov/


2/51

Contents

1 2D Structure

2 3D Conformer

3 Names and Identifiers4 Chemical and Physical Properties

5 Related Records

6 Chemical Vendors

7 Drug and Medication Information

8 Pharmacology and Biochemistry

9 Use and Manufacturing

10 Identification

11 Safety and Hazards

12 Toxicity

13 Literature

14 Patents

15 Biomolecular Interactions and Pathways

16 Biological Test Results

17 Classification

18 Information Sources


3/51

from PubChem

1 2D Structure

Magnify

Search Download Get Image


4/51

from PubChem

2 3D Conformer

Magnify

Show Hydrogens Show Atoms Interact

Search Download Get Image


5/51


6/51

617-082-4

from ECHA

O2GMZ0LF5W

from FDA/SPL Indexing data

3.2.3 UNII

3.3 Synonyms

1. Cutivate

2. Flixonase

3. Flixotide

4. Flonase

5. Flovent

6. fluticasone

7. fluticasone propionate

from MeSH

3.3.1 MeSH Synonyms

from PubChem

1. FLUTICASONE PROPIONATE

2. Cutivate

3. Flonase

4. Flovent

5. Flixonase

6. Flixotide

7. Flovent HFA

8. Flunase

9. atemur

10. Flusonal

11. Fluspiral

12. Flutide

13. Flovent Diskus 50



16. Asmatil

17. Axotide

18. Brethal

19. Fluinol

20. Flutivate

21. Inalacor

22. Rinosone

23. Trialona

24. Ubizol

25. Zoflut

26. Flixotide Disks

27. Flixotide Disk

28. Flovent Diskus

29. Flonase Aq

30. Flixotide Inhaler

31. Cutivate (TN)

32. Flixonase Nasal Spray

33. 80474-14-2

34. CCI-18781

35. Fluxonal

36. Skyron

37. Fluticasonpropionat All

38. Flonase (TN)

39. Flovent (TN)

40. CHEBI:31441

3.3.2 Depositor-Supplied Synonyms

http://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CHEBI%3A31441%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flovent%20(TN)%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flonase%20(TN)%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Fluticasonpropionat%20Allen%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Skyron%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Fluxonal%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22CCI-18781%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%2280474-14-2%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flixonase%20Nasal%20Spray%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Cutivate%20(TN)%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flixotide%20Inhaler%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flonase%20Aq%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flovent%20Diskus%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flixotide%20Disk%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flixotide%20Disks%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Zoflut%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Ubizol%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Trialona%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Rinosone%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Inalacor%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flutivate%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Fluinol%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Brethal%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Axotide%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Asmatil%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flovent%20Diskus%20250%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flovent%20Diskus%20100%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flovent%20Diskus%2050%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flutide%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Fluspiral%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flusonal%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22atemur%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flunase%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flovent%20HFA%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flixotide%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flixonase%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flovent%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Flonase%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22Cutivate%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.ncbi.nlm.nih.gov/pcsubstance/?term=%22FLUTICASONE%20PROPIONATE%22%5BCompleteSynonym%5D%20AND%20444036%5BStandardizedCID%5Dhttp://www.accessdata.fda.gov/spl/data/882786d7-2873-4997-8d3c-b5a403bc0fec/882786d7-2873-4997-8d3c-b5a403bc0fec.xml


7/51

4 Chemical and Physical Properties

Molecular Weight 500.57085 g/mol

Molecular Formula C H F O S

XLogP3 4

Hydrogen Bond Donor Count 1

Hydrogen Bond Acceptor Count 9

Rotatable Bond Count 6

Exact Mass 500.18443 g/mol

Monoisotopic Mass 500.18443 g/mol

Topological Polar Surface Area 106 A^2

Heavy Atom Count 34

Formal Charge 0

Complexity 984

Isotope Atom Count 0

Defined Atom Stereocenter Count 9

Undefined Atom Stereocenter Count 0

Defined Bond Stereocenter Count 0

Undefined Bond Stereocenter Count 0

Covalently-Bonded Unit Count 1

from PubChem

4.1 Computed Properties

25 31 3 5

4.2 Experimental Properties

272-273 °C

from DrugBank

4.2.1 Melting Point

In water, 102 mg/L at 25 deg C (est)

US EPA; Estimation Program Interface (EPI) Suite. Ver. 4.0. Jan, 2009. Available from, as of April 23, 2009:http://www.epa.gov/oppt/exposure/pubs/episuitedl.htm

from HSDB

4.2.2 Solubility

http://www.epa.gov/oppt/exposure/pubs/episuitedl.htmhttp://pubchem.ncbi.nlm.nih.gov/compound/waterhttp://pubchem.ncbi.nlm.nih.gov/search/#collection=compounds&query_type=mf&query=C25H31F3O5S&sort=mw&sort_dir=asc


8/51

Water Solubility

0.51 mg/L (insoluble)

from DrugBank

7.45X10-13 mm Hg at 25 deg C (est)


from HSDB

4.2.3 Vapor Pressure

log Kow = 1.40 (est)


from HSDB

3.4

from DrugBank

4.2.4 LogP

Crystal Structures: 1 of 2

CCDC Number 735705

Crystal Structure Data DOI:10.5517/ccspkff

Associated Article DOI:10.1039/a904702f

from The Cambridge Structural Database

Crystal Structures: 2 of 2

CCDC Number 290181

Crystal Structure Data DOI:10.5517/cc9qypm

from The Cambridge Structural Database

4.3 Crystal Structures

http://doi.org/10.5517/cc9qypmhttp://doi.org/10.5517/cc9qypmhttp://doi.org/10.1039/a904702fhttp://doi.org/10.5517/ccspkffhttp://doi.org/10.5517/ccspkffhttp://www.epa.gov/oppt/exposure/pubs/episuitedl.htmhttp://www.epa.gov/oppt/exposure/pubs/episuitedl.htm


9/51

5 Related Records

Medications (22) Literature (61) 3D Structure (2) Bioactivities (124) Patents (390)

from PubChem

5.1 Related Compounds with Annotation

fluticasone furoate medrysone

Same Connectivity 46 records

Same Stereo 4 records

Same Isotope 36 records

Same Parent, Connectivity 55 records

Same Parent, Stereo 9 records

Same Parent, Isotope 45 records

Same Parent, Exact 6 records

Mixtures, Components, andNeutralized Forms

31 records

Similar Compounds 2427 records

Similar Conformers 1485 records

from PubChem

5.2 Related Compounds

5.3 Substances

All 130 records

Same 69 records

5.3.1 Related Substances

Download

http://www.ncbi.nlm.nih.gov/pcsubstance/?term=444036[StandardizedCID]http://www.ncbi.nlm.nih.gov/pcsubstance/?term=444036[CompoundID]http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_3d&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_mixture&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_parent_pulldown&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_parent_isotopes_pulldown&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_parent_stereo_pulldown&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_parent_connectivity_pulldown&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_sameisotopic_pulldown&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_samestereochem_pulldown&from_uid=444036http://www.ncbi.nlm.nih.gov/pccompound?cmd=Link&LinkName=pccompound_pccompound_sameconnectivity_pulldown&from_uid=444036http://pubchem.ncbi.nlm.nih.gov/compounds/247839http://pubchem.ncbi.nlm.nih.gov/compounds/9854489


10/51

Mixture 61 records

from PubChem

Chemical Vendors (27)

Curation Efforts (1)

Governmental Organizations (5)

Journal Publishers (3)

NIH Initiatives (5)

Research and Development (28)

Subscription Services (5)

from PubChem

5.3.2 Substances by Category

PubMed 1205 records

Taxonomy 3 records

OMIM 1 record

Gene 39 records

from PubChem

5.4 Entrez Crosslinks

Download

http://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_gene&db=pccompound&cmd=Link&from_uid=444036http://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_omim&db=pccompound&cmd=Link&from_uid=444036http://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_taxonomy&db=pccompound&cmd=Link&from_uid=444036http://www.ncbi.nlm.nih.gov/sites/entrez?LinkName=pccompound_pubmed&db=pccompound&cmd=Link&from_uid=444036http://www.ncbi.nlm.nih.gov/pcsubstance/?term=444036[ComponentCID]


11/51

Vendor/Supplier Purchasable Chemical PubChem SID

DiscoveryGate 444036 10299475

ZINC ZINC03920027 71824933ChemScene CS-1986 210279272

Berrchem BR-72799 174476561

MedChemexpress MCE HY-B0154 210281595

AvaChem Scientific3062 251917852

80474-14-2 251916505

NIH Clinical Collection SAM001246583 46386601

labseeker

SC-18196 251884139

SC-19333 251877001

Wutech RS0009 174561017

ChemMol

2100037 126592957

30107690 126621864

44005454 126653604

A&J Pharmtech CO., LTD. AJ-47435 223556606

Chembase.cn 470 160963933

Syntree ST2407016 249827492

AKos Consulting & Solutions AKOS015895220 152034639

Hangzhou APIChem Technology AC-457 92717930

ABI Chem AC1L9FLD 104631189

Finetech Industry LimitedFT-0082893 118048889

FT-0626494 164810442

Key Organics/BIONET KS-1173 187072308

Boerchem BC216013 196105643Tocris Bioscience 2007 252156254

ABBLIS Chemicals AB1010912 131465790

Ambinter SBB071021 118318289

from PubChem

6 Chemical Vendors

Refine/Analyze Download

http://pubchem.ncbi.nlm.nih.gov/substance/118318289http://pubchem.ncbi.nlm.nih.gov/substance/131465790http://www.abblis.com/25291-17-2.htmlhttp://www.abblis.com/http://pubchem.ncbi.nlm.nih.gov/substance/252156254http://www.tocris.com/dispprod.php?ItemId=93860http://www.tocris.com/http://pubchem.ncbi.nlm.nih.gov/substance/196105643http://www.boerchemical.com/?product_36630.htmlhttp://www.boerchemical.com/http://pubchem.ncbi.nlm.nih.gov/substance/187072308http://www.keyorganics.net/shop/catalog/product/view/id/101282http://www.keyorganics.net/bionet/http://pubchem.ncbi.nlm.nih.gov/substance/164810442http://www.finetechnology-ind.com/product_detail.shtml?catalogNo=FT-0626494http://pubchem.ncbi.nlm.nih.gov/substance/118048889http://www.finetechnology-ind.com/http://pubchem.ncbi.nlm.nih.gov/substance/104631189http://www.abichem.com/http://pubchem.ncbi.nlm.nih.gov/substance/92717930http://www.apichemistry.com/http://pubchem.ncbi.nlm.nih.gov/substance/152034639http://akoscompounds.de/catalogue/akossamplesretrieval.php?IDNUMBERS=AKOS015895220http://www.akosgmbh.de/AKosSamples/index.htmlhttp://pubchem.ncbi.nlm.nih.gov/substance/249827492http://www.syntree.com/80474-14-2http://www.syntree.com/http://pubchem.ncbi.nlm.nih.gov/substance/160963933http://www.chembase.cn/molecule-470.htmlhttp://www.chembase.cn/http://pubchem.ncbi.nlm.nih.gov/substance/223556606http://www.ajpharmtech.com/http://www.ajpharmtech.com/http://pubchem.ncbi.nlm.nih.gov/substance/126653604http://www.chemmol.com/chemmol/44005454.htmlhttp://pubchem.ncbi.nlm.nih.gov/substance/126621864http://www.chemmol.com/chemmol/30107690.htmlhttp://pubchem.ncbi.nlm.nih.gov/substance/126592957http://www.chemmol.com/chemmol/2100037.htmlhttp://chemmol.com/suppliers/ChemMol/21/1/http://pubchem.ncbi.nlm.nih.gov/substance/174561017http://www.rennotech.com/product_show.asp?id=35612http://www.rennotech.com/http://pubchem.ncbi.nlm.nih.gov/substance/251877001http://www.labseeker.com/goods.php?id=43208http://pubchem.ncbi.nlm.nih.gov/substance/251884139http://www.labseeker.com/goods.php?id=19386http://www.labseeker.com/http://pubchem.ncbi.nlm.nih.gov/substance/46386601http://www.nihclinicalcollection.com/http://pubchem.ncbi.nlm.nih.gov/substance/251916505http://pubchem.ncbi.nlm.nih.gov/substance/251917852http://www.avachem.com/productSearch.asp?3062http://www.avachem.com/http://pubchem.ncbi.nlm.nih.gov/substance/210281595http://www.medchemexpress.com/Fluticasone-propionate.htmlhttp://www.medchemexpress.com/http://pubchem.ncbi.nlm.nih.gov/substance/174476561http://www.berrchem.com/http://pubchem.ncbi.nlm.nih.gov/substance/210279272http://www.chemscene.com/Fluticasone-propionate.htmlhttp://www.chemscene.com/http://pubchem.ncbi.nlm.nih.gov/substance/71824933http://zinc.docking.org/srchdb.pl?zinc=3920027http://zinc.docking.org/http://pubchem.ncbi.nlm.nih.gov/substance/10299475https://www.discoverygate.com/interlink/search?KeyName=EXTREG&KeyValue=444036&Database=INDEX&Source=PUBCHEMhttps://www.discoverygate.com/


12/51

7 Drug and Medication Information

Drug Information: 1 of 7

Drug Name Cutivate (from Drugs@FDA)

PubMed Health Fluticasone

Drug ClassesAnti-Inflammatory, Corticosteroid, Intermediate, Corticosteroid, Strong (fromPubMed Health)

Drug Label

CUTIVATE (fluticasone propionate cream) Cream, 0.05% contains fluticasonepropionate [(6,11,16,17)-6,9,-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)androsta-1,4-diene-17-carbothioic acid, S-fluoromethyl ester], asynthetic fluorina...Click here to see drug label(s) from DailyMed

Active Ingredient Fluticasone propionate

Dosage Form Lotion; Ointment

Route Topical

Strength 0.05%; 0.005%

Market Status Prescription

Company Fougera Pharms

Patent 7300669 (from FDA Orange Book )

from FDA Drugs, DailyMed, and PubMed Health


Drug Name Flonase (from Drugs@FDA)

Drug Label

Fluticasone propionate, the active component of FLONASE Nasal Spray, is asynthetic corticosteroid having the chemical name S-(fluoromethyl)6,9-difluoro-11-17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate,17-propionate and the...Click here to see drug label(s) from DailyMed


Dosage Form Spray, meteredRoute Nasal

Strength 0.05mg/spray


Company Glaxosmithkline



7.1 Drug Information

http://dailymed.nlm.nih.gov/dailymed/search.cfm?adv=1&labeltype=all&query=NAME:(FLONASE)http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=Fhttp://www.accessdata.fda.gov/scripts/cder/ob/http://dailymed.nlm.nih.gov/dailymed/search.cfm?adv=1&labeltype=all&query=NAME:(CUTIVATE)http://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0000767/http://pubchem.ncbi.nlm.nih.gov/compound/Fluticasonehttp://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=C


13/51

Drug Name Flovent diskus 100 (from Drugs@FDA)


Dosage Form Powder

Route Inhalation

Strength 0.1mg/inh


Company Glaxo Grp

Patent 5873360*PED; 5873360 (from FDA Orange Book )





Dosage Form Powder

Route Inhalation

Strength 0.25mg/inh


Company Glaxo Grp






Dosage Form Powder

Route Inhalation

Strength 0.05mg/inh


Company Glaxo Grp




Drug Name Flovent hfa (from Drugs@FDA)

Drug Label

The active component of FLOVENT HFA 44 mcg Inhalation Aerosol, FLOVENTHFA 110 mcg Inhalation Aerosol, and FLOVENT HFA 220 mcg Inhalation

http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=Fhttp://www.accessdata.fda.gov/scripts/cder/ob/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=Fhttp://www.accessdata.fda.gov/scripts/cder/ob/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=Fhttp://www.accessdata.fda.gov/scripts/cder/ob/http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=F


14/51

Aerosol is fluticasone propionate, a corticosteroid having the chemical nameS-(fluoromethyl) 6,9-difluoro-11...Click here to see drug label(s) from DailyMed


Dosage Form Aerosol, metered

Route Inhalation

Strength 0.22mg/inh; 0.11mg/inh; 0.044mg/inh


Company Glaxo Grp

Patent

7500444*PED; 5674472; 6966467; 5658549*PED; 6170717*PED; 6997349;6315173*PED; 7143908*PED; 6997349*PED; 6966467*PED; 6161724;6435372*PED; 5674472*PED; 6431168*PED; 6510969; 7107986; 7143908;6743413; 7832351; 6435372; 7500444; 6161724*PED; 6938796;6938796*PED; 5658549; 6431168; 7832351*PED; 7107986*PED; 6596260;7350676*PED; 6170717; 6315173; 6743413*PED; 7350676; 6510969*PED;6596260*PED (from FDA Orange Book )



Drug Name Fluticasone propionate (from Drugs@FDA)

Drug Label

Fluticasone propionate, the active component of Fluticasone PropionateNasal Spray USP, is a synthetic corticosteroid having the chemical name S-(fluoromethyl)6,9-difluoro-11-17-dihydroxy-16-methyl-3-oxoandrosta-1,4-diene-17-carbothioate, 17-...Click here to see drug label(s) from DailyMed


Dosage Form Ointment; Spray, metered; Cream; Lotion

Route Nasal; Topical

Strength 0.05%; 0.005%; 0.05mg/spray


CompanyWockhardt; Apotex; Roxane; Glenmark Generics; Fougera Pharms; Hi TechPharma; Perrigo New York; Tolmar; G And W Labs; Perrigo Israel


Androstadienes

National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)

from HSDB

Fluticasone propionate nasal spray is indicated for the management of the nasal symptoms of seasonal andperennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. /Included in USproduct label/

7.2 Therapeutic Uses

http://pubchem.ncbi.nlm.nih.gov/compound/Fougerahttp://dailymed.nlm.nih.gov/dailymed/search.cfm?adv=1&labeltype=all&query=NAME:(FLUTICASONE+PROPIONATE)http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchResults_Browse&DrugInitial=Fhttp://www.accessdata.fda.gov/scripts/cder/ob/http://dailymed.nlm.nih.gov/dailymed/search.cfm?adv=1&labeltype=all&query=NAME:(FLOVENT+HFA)


15/51

US Natl Inst Health; DailyMed. Current Medication Information for Flonase ( fluticasone propionate) spray (January 2008). Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6415

from HSDB

Fluticasone propionate cream is a medium potency corticosteroid indicated for the relief of the inflammatory andpruritic manifestations of corticosteroid-responsive dermatoses. Fluticasone propionate cream may be used withcaution in pediatric patients 3 months of age or older. The safety and efficacy of drug use for longer than 4 weeksin this population have not been established. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for Cutivate (fluticasone propionate) cream (April 2008).

Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340

from HSDB

Fluticasone propionate ointment is a medium potency corticosteroid indicated for the relief of the inflammatoryand pruritic manifestations of corticosteroid-responsive dermatoses in adult patients. /Included in US productlabel/

US Natl Inst Health; DailyMed. Current Medication Information for Cutivate (fluticasone propionate) ointment (August 2007). Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5097

from HSDB

Fluticasone propionate inhalation powder is indicated for the maintenance treatment of asthma as prophylactic

therapy in adult and pediatric patients 4 years of age and older. It is also indicated for patients requiring oralcorticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirementfor oral corticosteroids over time. /Included in US product label/

US Natl Inst Health; DailyMed. Current Medication Information for Flovent Diskus (fluticasone propionate) powder, metered (November 2008). Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742

from HSDB

Fluticasone propionate inhalation powder is NOT indicated for the relief of acute bronchospasm. /Included in USproduct label/


from HSDB

Intranasal fluticasone propionate generally is well tolerated. Adverse effects with intranasal fluticasonepropionate therapy usually are mild and local and resolve without specific treatment. The manufacturer statesthat systemic corticosteroid effects were not reported with fluticasone nasal spray in controlled trials of up to 6months' duration, but systemic effects (eg, growth suppression) have been reported with intranasalcorticosteroids, including fluticasone propionate, during postmarketing experience.

American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009) , p. 2895

from HSDB

The most frequent adverse effects of fluticasone propionate nasal spray involve the nasal mucous membranes.Epistaxis or sensations of nasal burning/irritation have been reported in 6-6.9 or 2.4-3.2%, respectively, of patientsreceiving fluticasone propionate (100-200 ug once daily) in controlled studies. These adverse effects usually areof short duration and rarely require changes in or discontinuance of therapy. Sensations of nasal burning mayresult from excipients in the commercially available preparation since the frequency and severity of these effectsare similar in patients receiving an intranasal placebo vehicle with identical inactive ingredients. In addition, thesimilar occurrence of adverse nasal effects in fluticasone propionate- or placebo-treated patients with seasonalor perennial rhinitis may result from physical contact and irritation of the characteristically sensitive nasalpassages of these patients. Pharyngitis or cough has been reported in 6-7.8 or 3.6-3.8%, respectively, of patientsreceiving the drug. Symptoms of asthma have occurred in 7.2 or 3.3% of those receiving 100 or 200 ug,

7.3 Drug Warning

http://pubchem.ncbi.nlm.nih.gov/compound/fluticasonehttp://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5097http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6415


16/51

respectively, of fluticasone propionate once daily.


from HSDB

Other adverse nasopharyngeal or respiratory effects occurring in 1-3% of patients receiving fluticasonepropionate nasal spray include nasal secretions containing blood, nasal discharge, and bronchitis. Sneezing,rhinorrhea, sinusitis, sore throat, throat irritation and dryness, hoarseness, voice changes, alteration or loss of sense of taste and/or smell, nasal congestion or blockage, or nasal dryness has been reported in patientsreceiving fluticasone propionate nasal spray in controlled studies or during postmarketing surveillance. Nasal

septum excoriation, ulceration, or nasal septum crusting also has been reported in patients receiving fluticasonepropionate nasal spray. It has been suggested that nasal septum crusting, nasal dryness accompanied by nasalmanipulation ("picking"), or nasal bleeding may predispose to the development of nasal perforation, which hasbeen reported rarely with intranasal administration of corticosteroids, including fluticasone propionate. In 2patients who experienced nasal perforation with fluticasone propionate, both had previous septal surgery thatmay have increased the risk of nasal perforation.


from HSDB

Localized candidal infections of the nose and/or pharynx have occurred rarely during fluticasone propionatetherapy. If a candidal infection is suspected, appropriate local anti-infective therapy and/or discontinuance of

intranasal corticosteroid therapy should be considered. Upper respiratory infection also has been reported withintranasal fluticasone propionate therapy, but a causal relationship to the drug has not been established


from HSDB

Although not reported to date in patients receiving fluticasone propionate or other intranasal corticosteroids,some clinicians caution that atrophic rhinitis potentially could develop during chronic therapy with an intranasalcorticosteroid, since atrophic dermatitis has occurred in patients treated with topical corticosteroids to the skinfor prolonged periods. However, the theoretical potential for nasal atrophy is thought to be less than that foratrophic dermatitis because of the smaller residence time of the intranasal corticosteroid on the nasal mucosacompared with that of topical corticosteroids on the skin. Rhinoscopic assessment or nasal examination of patients with rhinitis treated continuously with intranasal fluticasone propionate for 6-12 months has shown no

evidence of serious mucosal damage. American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009) , p. 2895

from HSDB

Adrenal suppression, based on mean plasma cortisol, morning plasma cortisol, or urinary 17-ketogenic steroid(17-KS) determinations, has not been observed to date when fluticasone propionate was administeredintranasally in adults receiving 200 ug daily for up to 12 months or in children (aged 4-11 years) receivingintranasal fluticasone spray 100-200 ug daily for 2-4 weeks. In addition, no evidence of growth suppression wasnoted in a 1-year, placebo-controlled study in children 3-9 years of age receiving fluticasone propionate 200 ugonce daily... While no clinically important alterations in plasma cortisol were observed in patients with asthmareceiving orally inhaled fluticasone propionate dosages of 200-1500 ug daily for up to 1 year, a relationshipbetween plasma fluticasone propionate concentrations and inhibitory effects on stimulated cortisol production

has been demonstrated after 4 weeks of treatment with fluticasone propionate inhalation aerosol. ...Themanufacturer states that although systemic effects have been minimal with recommended doses of fluticasonepropionate nasal spray, the potential risk of such effects increases with larger doses; therefore, larger-than-recommended doses of fluticasone propionate nasal spray should be avoided. The effect of intranasalfluticasone propionate on the HPA-axis response to stress (eg, surgery) is not known. Intranasal administration of usual dosages of fluticasone propionate apparently produces less HPA-axis suppression than intranasaladministration of usual dosages of dexamethasone phosphate; however, comparative studies have not beenconducted to date.


from HSDB

http://pubchem.ncbi.nlm.nih.gov/compound/dexamethasone%20phosphatehttp://pubchem.ncbi.nlm.nih.gov/compound/cortisolhttp://pubchem.ncbi.nlm.nih.gov/compound/cortisolhttp://pubchem.ncbi.nlm.nih.gov/compound/fluticasonehttp://pubchem.ncbi.nlm.nih.gov/compound/cortisolhttp://pubchem.ncbi.nlm.nih.gov/compound/cortisol


17/51

Headache has been reported in 6.6-16.1% of patients receiving intranasal fluticasone propionate therapy.Menstrual cramps also have been reported in patients receiving the drug, although a causal relationship has notbeen established. Nausea and vomiting have been reported in 2.6-4.8% of adults and children receivingfluticasone in controlled clinical trials. Dizziness, abdominal pain, diarrhea, fever, flu-like symptoms, or aches andpains have been reported in 1-3% of adults and children receiving fluticasone in controlled clinical trials.Drowsiness/lethargy/fatigue or arthralgia has occurred infrequently in patients receiving intranasal fluticasonepropionate. Immediate hypersensitivity reactions (eg, wheezing, contact dermatitis, rash, dyspnea,anaphylaxis/anaphylactoid reactions, pruritus, urticaria, angioedema, edema of the face and tongue,bronchospasm) have been reported during postmarketing surveillance or in controlled clinical trials with

intranasal administration of fluticasone propionate. American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009) , p. 2895

from HSDB

Cataracts, ocular dryness and irritation, conjunctivitis, blurred vision, glaucoma, and increased intraocularpressure have been reported with intranasal administration of corticosteroids, including fluticasone. In acontrolled, comparative study, ophthalmologic abnormalities (eg, retinal changes, lenticular opacities) were notedafter 12 and 24 weeks of therapy in a similar percentage of patients receiving intranasal fluticasone propionate,beclomethasone, or placebo; however, none of the ocular changes were of the type attributed to systemic effectsof corticosteroid therapy (eg, posterior subcapsular cataracts, increased intraocular pressure).


from HSDB

Although systemic effects have been minimal with recommended dosages of fluticasone propionate nasal spray,potential risk increases with higher dosages. Therefore, higher than recommended dosages of fluticasonepropionate nasal spray should be avoided since hypercorticism and suppression of HPA function may occur. If such systemic effects occur, the dosage of fluticasone propionate nasal spray should be reduced slowly and thedrug discontinued in accordance with accepted procedures for discontinuing oral corticosteroid therapy


from HSDB

Fluticasone propionate nasal spray should be used with caution in patients receiving systemic corticosteroids in

an alternate-day or daily dosing regimen for any disease, since concomitant use of the drugs could increase thelikelihood of HPA-axis suppression compared with therapeutic dosages of either drug alone. In addition,concomitant use of fluticasone propionate nasal spray with other inhaled corticosteroids could increase the riskof manifestations of hypercorticism and/or suppression of HPA function.


from HSDB

Patients who have received systemic corticosteroids for prolonged periods and are being switched to treatmentwith topical corticosteroids (eg, fluticasone propionate nasal spray) should be monitored carefully sincecorticosteroid withdrawal symptoms (eg, joint pain, muscular pain, lassitude, depression), acute adrenalinsufficiency, or severe symptomatic exacerbation of asthma or other clinical conditions may occur.

American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009) , p. 2895 from HSDB

Although manifestations of Cushing's syndrome (eg, hypertension, glucose intolerance, cushingoid features)have not been associated with intranasal fluticasone propionate therapy to date, the possibility of theiroccurrence should be considered in patients who are particularly sensitive to corticosteroid effects or when usualdosages of the drug are exceeded.


from HSDB

Patients should be advised that intranasal fluticasone propionate should be used at regular intervals to be

http://pubchem.ncbi.nlm.nih.gov/compound/glucosehttp://pubchem.ncbi.nlm.nih.gov/compound/beclomethasonehttp://pubchem.ncbi.nlm.nih.gov/compound/retinalhttp://pubchem.ncbi.nlm.nih.gov/compound/fluticasonehttp://pubchem.ncbi.nlm.nih.gov/compound/fluticasonehttp://pubchem.ncbi.nlm.nih.gov/compound/fluticasone


18/51

therapeutically effective. In addition, patients generally should be advised that the full benefits of the drug maynot be achieved for several days and that use of topical nasal decongestants or oral antihistamines may benecessary until the effects of intranasal fluticasone propionate therapy are fully manifested. Patients also shouldbe advised not to exceed the prescribed dosage. Patients with severe allergies should be instructed to avoidexposure to allergens during intranasal fluticasone propionate therapy to prevent the occurrence of severeallergic symptoms in the eyes and/or lower respiratory tract. Patients should be instructed to contact theirphysician during intranasal fluticasone propionate therapy if signs or symptoms of the condition do not improve,if the condition worsens, or if sneezing or nasal irritation occurs.


from HSDB

Glucocorticoids, especially in large doses, increase susceptibility to and mask symptoms of infection. Because of the inhibitory effect of these drugs on wound healing, patients with recent nasal septal ulcers, nasal surgery, ornasal trauma should not use intranasal corticosteroids until healing has occurred.


from HSDB

Patients who are taking immunosuppressant drugs while receiving corticosteroids have increased susceptibilityto infections compared with healthy individuals, and certain infections (eg, varicella [chickenpox], measles) canhave a more serious or even fatal outcome in such patients, particularly in children. In patients who have not had

these diseases, particular care should be taken to avoid exposure. The relationship of dose, route of administration, and duration of corticosteroid therapy to the risk of developing a disseminated infection is notknown, nor is the contribution of the underlying disease and/or prior corticosteroid therapy. Patients receivingcorticosteroids who are potentially immunosuppressed should be warned of the risk of exposure to certaininfections (eg, chickenpox, measles) and of the importance of obtaining medical advice if such exposure occurs.If exposure to varicella or measles occurs in such individuals, administration of varicella zoster immune globulin(VZIG) or immune globulin, respectively, may be indicated. If varicella develops, treatment with an antiviral agent(eg, acyclovir) may be considered.


from HSDB

Fluticasone propionate nasal spray is contraindicated in patients with known hypersensitivity to the drug or other

ingredients in the formulation (the formulation does not contain fluorocarbons). American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009) , p. 2897

from HSDB

Use of excessive dosages of corticosteroids may lead to manifestations of hypercorticism, suppression of HPAfunction, and/or suppression of growth in children or adolescents. Inhibitory effects on short-term growth rate (asdetermined by knemometry studies of lower leg growth) have been observed in asthmatic children andadolescents receiving orally inhaled corticosteroids (eg, beclomethasone dipropionate, fluticasone propionate).However, the relationship between short-term changes in lower leg growth and long-term effects on growthcurrently are unclear. ... Clinicians should monitor closely (eg, via stadiometry) the growth of children andadolescents taking corticosteroids by any route of administration; if growth rate is affected, the clinician shouldweigh the potential benefits of corticosteroid therapy against the possibility of growth suppression.


from HSDB

Fluticasone propionate should be used with caution in nursing women, since it is not known whether the drug isdistributed into milk in humans.


from HSDB

FDA Pregnancy Risk Category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies arelacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if

http://pubchem.ncbi.nlm.nih.gov/compound/beclomethasone%20dipropionatehttp://pubchem.ncbi.nlm.nih.gov/compound/acyclovir


19/51

the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./


from HSDB

During postmarketing use, there have been reports of clinically significant drug interactions in patients receivingfluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing syndrome andadrenal suppression. Therefore, coadministration of fluticasone propionate and ritonavir is not recommendedunless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.


from HSDB

Intranasal corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculousinfections of the respiratory tract; untreated local or systemic fungal or bacterial infections; systemic viral orparasitic infections; or ocular herpes simplex.


from HSDB

In clinical studies with fluticasone propionate administered intranasally, the development of localized infectionsof the nose and pharynx with Candida albicans has occurred only rarely. When such an infection develops, it mayrequire treatment with appropriate local therapy and discontinuation of treatment with Fluticasone propionatenasal spray. Patients using Fluticasone propionate nasal spray over several months or longer should beexamined periodically for evidence of Candida infection or other signs of adverse effects on the nasal mucosa.


from HSDB

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses /of topical fluticasonepropionate/ due to their larger skin surface to body mass ratios.

US Natl Inst Health; DailyMed. Current Medication Information for Cutivate (fluticasone propionate) cream (April 2008). Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340

from HSDB

Fluticasone propionate cream contains the excipient imidurea which releases traces of formaldehyde as abreakdown product. Formaldehyde may cause allergic sensitization or irritation upon contact with the skin.


from HSDB

If irritation develops, Fluticasone propionate cream should be discontinued and appropriate therapy instituted.

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather thannoting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observationshould be corroborated with appropriate diagnostic patch testing.


from HSDB

Parents of pediatric patients should be advised not to use this medication in the treatment of diaper dermatitis.Fluticasone propionate cream should not be applied in the diaper areas as diapers or plastic pants mayconstitute occlusive dressing.

US Natl Inst Health; DailyMed. Current Medication Information for Cutivate (fluticasone propionate) cream (April 2008).

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://pubchem.ncbi.nlm.nih.gov/compound/Formaldehydehttp://pubchem.ncbi.nlm.nih.gov/compound/formaldehydehttp://pubchem.ncbi.nlm.nih.gov/compound/imidureahttp://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6415http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6415http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6415http://pubchem.ncbi.nlm.nih.gov/compound/ritonavirhttp://pubchem.ncbi.nlm.nih.gov/compound/ritonavirhttp://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6415


20/51

Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340

from HSDB

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere withendogenous corticosteroid production, or cause other untoward effects. It is not known whether topicaladministration of corticosteroids could result in sufficient systemic absorption to produce detectable quantitiesin human milk.


from HSDB

This medication should not be used on the face, underarms, or groin areas unless directed by a physician.


from HSDB

HPA axis suppression, Cushing syndrome, linear growth retardation, delayed weight gain, and intracranialhypertension have been reported in pediatric patients receiving topical corticosteroids. ... Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.


from HSDB

The total incidence of adverse reactions associated with the use of Fluticasone propionate cream wasapproximately 4%. These adverse reactions were usually mild; self-limiting; and consisted primarily of pruritus,dryness, numbness of fingers, and burning. These events occurred in 2.9%, 1.2%, 1.0%, and 0.6% of patients,respectively.


from HSDB

The following local adverse reactions have been reported infrequently with topical corticosteroids, and they mayoccur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactionsare listed in an approximately decreasing order of occurrence: irritation, folliculitis, acneiform eruptions,hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, andmiliaria. Also, there are reports of the development of pustular psoriasis from chronic plaque psoriasis followingreduction or discontinuation of potent topical corticosteroid products.


from HSDB

Fluticasone propionate inhalation powder is contraindicated in the primary treatment of status asthmaticus or

other acute episodes of asthma where intensive measures are required.US Natl Inst Health; DailyMed. Current Medication Information for Flovent Diskus (fluticasone propionate) powder, metered (November 2008). Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742

from HSDB

Particular care is needed for patients who are transferred from systemically active corticosteroids to fluticasonepropionate inhalation powder because deaths due to adrenal insufficiency have occurred in patients with asthmaduring and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids.After withdrawal from systemic corticosteroids, a number of months are required for recovery of HPA function.


http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340


21/51

from HSDB

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may bemost susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn.During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency whenexposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severeelectrolyte loss. Although fluticasone propionate inhalation powder may provide control of asthma symptomsduring these episodes, in recommended doses it supplies less than normal physiological amounts of corticosteroid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with

these emergencies.US Natl Inst Health; DailyMed. Current Medication Information for Flovent Diskus (fluticasone propionate) powder, metered (November 2008). Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742

from HSDB

During periods of stress or a severe asthma attack, patients who have been withdrawn from systemiccorticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contacttheir physicians for further instruction. These patients should also be instructed to carry a warning cardindicating that they may need supplementary systemic corticosteroids during periods of stress or a severeasthma attack.


from HSDB

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use aftertransferring to fluticasone propionate inhalation powder. ...Lung function (FEV1 or AM PEF), beta-agonist use,and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition tomonitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenalinsufficiency such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.


from HSDB

Transfer of patients from systemic corticosteroid therapy to fluticasone propionate inhalation powder mayunmask conditions previously suppressed by the systemic corticosteroid therapy, eg, rhinitis, conjunctivitis,eczema, arthritis, and eosinophilic conditions.


from HSDB

Fluticasone propionate inhalation powder is not to be regarded as a bronchodilator and is not indicated for rapidrelief of bronchospasm.


from HSDB

As with other inhaled medications, bronchospasm may occur with an immediate increase in wheezing afterdosing. If bronchospasm occurs following dosing with fluticasone propionate inhalation powder, it should betreated immediately with a fast-acting inhaled bronchodilator. Treatment with fluticasone propionate inhalationpowder should be discontinued and alternative therapy instituted.


from HSDB

Patients should be instructed to contact their physicians immediately when episodes of asthma that are not

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://pubchem.ncbi.nlm.nih.gov/compound/prednisone


22/51

responsive to bronchodilators occur during the course of treatment with fluticasone propionate inhalationpowder. During such episodes, patients may require therapy with oral corticosteroids.


from HSDB

In rare cases, patients on inhaled fluticasone propionate may present with systemic eosinophilic conditions, withsome patients presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome /(allergiceosinophilic vasculitis)/, a condition that is often treated with systemic corticosteroid therapy. These events

usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapyfollowing the introduction of fluticasone propionate. Cases of serious eosinophilic conditions have also beenreported with other inhaled corticosteroids in this clinical setting. Physicians should be alert to eosinophilia,vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in theirpatients. A causal relationship between fluticasone propionate and these underlying conditions has not beenestablished.


from HSDB

Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory andpruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergicrhinitis, and orally for the maintenance treatment of asthma as prophylactic therapy and for patients requiringoral corticosteroid therapy for asthma.

from DrugBank

7.4 Drug Indication

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742


23/51

8 Pharmacology and Biochemistry

Fluticasone is an extremely potent vasoconstrictor and anti-inflammatory agent. Its effectiveness in inhaledforms is due to its direct local effect.

from DrugBank

Fluticasone Propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoidreceptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of theglucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2,which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins andleukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads todephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription.Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.

from NCIt

8.1 Pharmacology

Dermatologic Agents

Drugs used to treat or prevent skin disorders or for the routine care of skin. See a list of PubChem compoundsmatching this category.

from MeSH

Anti-Inflammatory Agents

Substances that reduce or suppress INFLAMMATION. See a list of PubChem compounds matching thiscategory.

from MeSH

Bronchodilator Agents

Agents that cause an increase in the expansion of a bronchus or bronchial tubes. See a list of PubChemcompounds matching this category.

from MeSH

Anti-Allergic Agents

Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatorymediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug EvaluationsAnnual, 1994, p475) See a list of PubChem compounds matching this category.

from MeSH

8.2 MeSH Pharmacological Classification

Fluticasone propionate is poorly absorbed from the respiratory and GI tracts following nasal inhalation of thedrug as an aqueous spray. Based on indirect calculations, intranasal fluticasone propionate has an absolutesystemic bioavailability of less than 2%. A major portion of an intranasal dose of corticosteroids is swallowed and

8.3 Absorption, Distribution and Excretion

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&DbFrom=mesh&Cmd=Link&LinkName=mesh_pccompound&IdsFromResult=68018926http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&DbFrom=mesh&Cmd=Link&LinkName=mesh_pccompound&IdsFromResult=68001993http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&DbFrom=mesh&Cmd=Link&LinkName=mesh_pccompound&IdsFromResult=68000893http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pccompound&DbFrom=mesh&Cmd=Link&LinkName=mesh_pccompound&IdsFromResult=68003879http://pubchem.ncbi.nlm.nih.gov/compound/fluticasonehttp://pubchem.ncbi.nlm.nih.gov/compound/propionatehttp://pubchem.ncbi.nlm.nih.gov/compound/Fluticasone


24/51

undergoes extensive first-pass metabolism in the liver. In patients with allergic rhinitis receiving intranasalfluticasone propionate for 2-3 weeks, plasma concentrations were above the level of detection of the assay (50pg/mL) only when recommended dosages were exceeded, and in those instances, only in occasional samples atlow concentrations.


from HSDB

Limited data from studies in which radiolabeled fluticasone propionate has been administered orally indicate thatthe drug is poorly absorbed from the GI tract and undergoes rapid first-pass metabolism in the liver. Preliminary

data from a dose-ranging study suggests that the amount of unchanged fluticasone propionate in plasmaincreases with dose following oral administration, but the bioavailability of the radiolabeled drug averaged about1% or less after oral doses of 1-40 mg.


from HSDB

Following oral administration of 1 or 16 mg of radiolabeled propionylfluticasone in a few healthy individuals, peakplasma radioactivity levels (expressed as fluticasone propionate equivalents) averaging approximately 1.3 or 9.1ng/mL, respectively, were achieved within 0.5-6 hours. Since no unchanged fluticasone propionate was detectedin plasma for up to 6 hours after oral administration of unlabeled fluticasone propionate given on a separateoccasion, the plasma radioactivity noted after administration of the radiolabeled drug was presumed to be

fluticasone propionate metabolites. It has been suggested that the presence of small amounts (50-170 pg/mL) of fluticasone propionate in plasma from 6-24 hours after the dose in these individuals potentially may representrectal reabsorption of unmetabolized drug.


from HSDB

The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including thevehicle and the integrity of the epidermal barrier. Occlusive dressing enhances penetration. Topicalcorticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in theskin increase percutaneous absorption.


from HSDB

In a human study of 12 healthy males receiving 12.5 g of 0.05% fluticasone propionate cream twice daily for 3weeks, plasma levels were generally below the level of quantification (0.05 ng/mL). In another study of 6 healthymales administered 25 g of 0.05% fluticasone propionate cream under occlusion for 5 days, plasma levels of fluticasone ranged from 0.07 to 0.39 ng/mL.


from HSDB

In an animal study using radiolabeled 0.05% fluticasone propionate cream and ointment preparations, rats

received a topical dose of 1 g/kg for a 24-hour period. Total recovery of radioactivity was approximately 80% atthe end of 7 days. The majority of the dose (73%) was recovered from the surface of the application site. Lessthan 1% of the dose was recovered in the skin at the application site. Approximately 5% of the dose was absorbedsystemically through the skin. Absorption from the skin continued for the duration of the study (7 days),indicating a long retention time at the application site.


from HSDB

...The majority of the fluticasone propionate delivered to the lung is systemically absorbed. The systemicbioavailability of fluticasone propionate from the Diskus device in healthy volunteers averages 18%.

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://pubchem.ncbi.nlm.nih.gov/compound/fluticasonehttp://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340


25/51


from HSDB

Systemic exposure as measured by AUC in healthy subjects (N = 24) who received 8 inhalations, as a single dose,of fluticasone propionate HFA using the 44-, 110-, and 220-ug strengths increased proportionally with dose. Thegeometric means (95% CI) of AUC0-24 hr for the 44-, 110-, and 220-ug strengths were 488 (362, 657); 1,284 (904;1,822); and 2,495 (1,945; 3,200) pg.hr/mL, respectively, and the geometric means of Cmax were 126 (108, 148),254 (202, 319), and 421 (338, 524) pg/mL, respectively. Systemic exposure from fluticasone propionate HFA 220

ug was 30% lower than that from the fluticasone propionate CFC inhaler. Systemic exposure was measured inpatients with asthma who received 2 inhalations of fluticasone propionate HFA 44 ug (n = 20), 110 ug (n = 15), or220 ug (n = 17) twice daily for at least 4 weeks. The geometric means (95% CI) of AUC0-12 hr for the 44-, 110-,and 220-ug strengths were 76 (33, 175), 298 (191, 464), and 601 (431, 838) pg.hr/mL, respectively. Cmax occurredin about 1 hour, and the geometric means were 25 (18, 36), 61 (46, 81), and 103 (73, 145) pg/mL, respectively.

US Natl Inst Health; DailyMed. Current Medication Information for Flovent-HFA (fluticasone propionate) aerosol, metered (July 2008). Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7947

from HSDB

Peak steady-state fluticasone propionate plasma concentrations in adult patients with asthma (N = 11) rangedfrom undetectable to 266 pg/mL after a 500-mcg twice-daily dosage of fluticasone propionate inhalation powderusing the Diskus device. The mean fluticasone propionate plasma concentration was 110 pg/mL.


from HSDB

Although fluticasone propionate is widely distributed into most tissues following iv administration, distribution of the drug following intranasal administration has not been described. Following iv administration, the volume of distribution for fluticasone propionate is 4.2 L/kg. Fluticasone propionate is approximately 91% bound to humanplasma proteins; protein binding demonstrates no obvious relationship to drug concentration. Fluticasonepropionate is weakly and reversibly bound to erythrocytes and equilibrates freely between erythrocytes andplasma. Fluticasone propionate is not appreciably bound to human transcortin (corticosteroid-binding globulin).


from HSDB

Fluticasone propionate crosses the placenta in rats or rabbits following oral administration of fluticasonepropionate 100 or 300 ug/kg, respectively (approximately 4 or 25 times, respectively, the maximum dailyintranasal dosage in adults on a ug/sq m basis). It is not known if fluticasone propionate is distributed intohuman milk following intranasal administration; however, other corticosteroids are distributed into human milk.


from HSDB

In lactating rats, subcutaneous administration of tritiated fluticasone propionate (10 ug/kg, approximately one-third the maximum recommended daily intranasal dosage in adults on a ug/sq m basis) resulted in measurable

radioactivity in both plasma and milk. American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009) , p. 2897

from HSDB

Plasma clearance of the drug ranges from 623-998 mL/minute; total blood clearance (plasma clearance adjustedfor packed cell volume) of iv fluticasone propionate averages 1093 mL/minute and approximates that of liverblood flow, with renal clearance accounting for less than 0.02% of total body clearance.


from HSDB

Following oral administration of radiolabeled drug, less than 5% of the dose was excreted in urine. ...Total fecal

http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7947http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=8742


26/51

excretion of fluticasone propionate has been reported to range from 87-100% of the oral dose. In 2 healthy menreceiving oral fluticasone propionate, fecal recovery of unchanged drug was 9 and 20% after a 1-mg dose and 54and 75% after a 16-mg dose. The increase in fecal excretion of unchanged fluticasone propionate with increaseddose has been attributed to insolubility of the drug rather than to biliary elimination. ... When a single oral 5-mgdose of fluticasone propionate was administered to patients with an ileostomy, 73% of the dose was recovered inthe ileostomy effluent within 12 hours.


from HSDB

The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including thevehicle and the integrity of the epidermal barrier. Bioavailability, intranasal =


27/51

from HSDB

Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man.

from DrugBank

Following intravenous dose of 1 mg in healthy volunteers, fluticasone propionate showed polyexponentialkinetics and had an average terminal half-life of 7.2 hours (range, 3.2 to 11.2 hours).


from HSDB

The apparent elimination half-life of fluticasone propionate after iv administration is approximately 3 hours.


from HSDB

Terminal elimination half-life = 7.8 hours

from DrugBank

8.5 Biological Half-Life

Fluticasone propionate is a highly selective agonist at the human glucocorticoid receptor with negligible activityat androgen, estrogen, or mineralocorticoid receptors. In preclinical studies, fluticasone propionate reportedlyexhibited weak progesterone-like activity. However, as plasma concentrations of fluticasone propionate are very

low following intranasal administration of the drug in recommended doses, the clinical importance of this findingis not known. The therapeutic effects of fluticasone propionate are thought to result from local actions of thedeposited inhaled dose on the nasal mucosa rather than from the systemic actions of the swallowed portion of the dose.


from HSDB

The exact mechanism(s) of anti-inflammatory action of corticosteroids in allergic rhinitis remains unknown, butmay involve reductions in the following: number of mediator cells (basophils, eosinophils, helper-inducer [CD4+,T4] T-cells, mast cells, and neutrophils) in the nasal mucosa, nasal reactivity to allergens, and release of inflammatory mediators and proteolytic enzymes. Following exposure of patients with a history of allergic rhinitisto allergen, eosinophils, basophils, mast cells, T cells, and neutrophils appear to infiltrate nasal secretions and

mucosa, releasing inflammatory mediators that generate allergic responses such as pruritus, sneezing,rhinorrhea, and nasal edema. /Corticosteroids/


from HSDB

Other mechanisms by which corticosteroids may improve symptoms of allergic rhinitis may involve inhibition of postcapillary venule dilation and permeability and facilitation of nasomucociliary clearance of nasal secretions.Patients receiving short- and long-term treatment with intranasal fluticasone propionate have demonstrateddecreases in nasal turbinate swelling and mucosal inflammation. As inflammatory changes occur during periodsof increased nasal hyperresponsiveness, the degree of response to nasal secretory stimuli has been used as anindirect measure of inflammation. In patients with asymptomatic seasonal allergic rhinitis, pretreatment withintranasal fluticasone propionate for 2-6 weeks prior to challenge with allergens or inflammatory

8.6 Mechanism of Action

http://pubchem.ncbi.nlm.nih.gov/compound/progesteronehttp://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340


28/51

mediatorsgenerally reduced the release of tryptase, histamine, eosinophilic cationic protein, and prostaglandin D2in nasal biopsies or nasal lavage fluid; concentrations of eosinophils or activated eosinophils, CD4+ T-cells, andbasophils also were reduced. /Corticosteroids/


from HSDB

Like other topical corticosteroids, fluticasone propionate has anti-inflammatory, antipruritic, and vasoconstrictiveproperties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear.However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively

called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor,arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.


from HSDB

Binds to the glucocorticoid receptor. Unbound corticosteroids cross the membranes of cells such as mast cellsand eosinophils, binding with high affinity to glucocorticoid receptors (GR). The results include alteration of transcription and protein synthesis, a decreased release of leukocytic acid hydrolases, reduction in fibroblastproliferation, prevention of macrophage accumulation at inflamed sites, reduction of collagen deposition,

interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability andsubsequent edema, reduction of complement components, inhibition of histamine and kinin release, andinterference with the formation of scar tissue. In the management of asthma, the glucocorticoid receptorcomplexes down-regulates proinflammatory mediators such as interleukin-(IL)-1, 3, and 5, and up-regulates anti-inflammatory mediators such as IkappaB [inhibitory molecule for nuclear factor kappaB1], IL-10, and IL-12. Theantiinflammatory actions of corticosteroids are also thought to involve inhibition of cytosolic phospholipase A2(through activation of lipocortin-1 (annexin)) which controls the biosynthesis of potent mediators of inflammationsuch as prostaglandins and leukotrienes.

from DrugBank

http://pubchem.ncbi.nlm.nih.gov/compound/histaminehttp://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=7340http://pubchem.ncbi.nlm.nih.gov/compound/Arachidonic%20acidhttp://pubchem.ncbi.nlm.nih.gov/compound/arachidonic%20acidhttp://pubchem.ncbi.nlm.nih.gov/compound/prostaglandin%20D2http://pubchem.ncbi.nlm.nih.gov/compound/histamine


29/51

9 Use and Manufacturing

6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17-propanoyloxy)androsta-1,4-diene-17beta-carboxylicacid

Council of Europe, European Directorate for the Quality of Medicines. European Pharmacopoeia, 5th Ed., Volume 2; Strasbourg,France, p.1628 (2004)

from HSDB

[(6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17-(propanoyloxy)androsta-1,4-dien-17beta-yl]carbonyl]sulphenic acid


from HSDB

6alpha,9-difluoro-17-[[(fluoromethyl)sulpanyl]carbonyl]-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-

17alpha-yl acetateCouncil of Europe, European Directorate for the Quality of Medicines. European Pharmacopoeia, 5th Ed., Volume 2; Strasbourg,France, p.1628 (2004)

from HSDB

6alpha,9-difluoro-17-[(methylsulphanyl)carbonyl]-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl propanoate


from HSDB

6alpha,9difluoro-17[[(fluoromethyl)sulphanyl]carbonyl]-16alpha-methyl-2,11-dioxoandrosta-1,4-dien-17alpha-ylpropanoate


from HSDB

6alpha,9difluoro-17-[[(fluoromethyl)sulphanyl]carbonyl]-11beta-hydroxy-16alpha-methyl-3-oxoandrost-4-en-17alpha-yl propanoate


from HSDB

6alpha,9-difluoro-17-[[(fluoromethyl)sulphanyl]carbonyl]-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl 6alpha,9-difluoro-11beta,17-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carboxylate


from HSDB

17,17'-(disulphanediyldicarbonyl)bis(6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl) dipropanoate


9.1 Impurities


30/51

from HSDB

17,17'-(trisulphanediyldicarbonyl)bis(6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-dien-17alpha-yl) dipropanoate


from HSDB

Fluticasone propionate nasal spray is an aqueous suspension of microfine fluticasone propionate for topicaladministration to the nasal mucosa by means of a metering, atomizing spray pump. Fluticasone propionate nasalspray also contains microcrystalline cellulose and carboxymethylcellulose sodium, dextrose, 0.02% w/wbenzalkonium chloride, polysorbate 80, and 0.25% w/w phenylethyl alcohol, and has a pH between 5 and 7./Fluticasone propionate/


from HSDB

Each gram of fluticasone propionate cream contains fluticasone propionate 0.5 mg in a base of propylene glycol,mineral oil, cetostearyl alcohol, Ceteth-20, isopropyl myristate, dibasic sodium phosphate, citric acid, purifiedwater, and imidurea as preservative. /Fluticasone propionate/


from HSDB

Each gram of fluticasone propionate ointment contains fluticasone propionate 0.05 mg in a base of liquidparaffin, microcrystalline wax, propylene glycol, and sorbitan sesquioleate. /Fluticasone propionate/

US Natl Inst Health; DailyMed. Current Medication Information for Cutivate (fluticasone propionate) ointment (August 2007).

Available from, as of June 29, 2009: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=5097 from HSDB

Fluticasone propionate Diskus is a specially designed plastic inhalation delivery system containing a double-foilblister strip of a powder formulation of fluticasone propionate in

Documents

Fluticasone Propionate _ c25h31f3o5s - Pubchem